Cite
MLA Citation
Cesar Perez et al.. “256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699).” Journal for immunotherapy of cancer, vol. 8, n.d., p. A155. http://access.bl.uk/ark:/81055/vdc_100144725746.0x000005